Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas

Molecular Medicine Reports

Volumn 6, Issue 2, 2012, Pages 391-394

  Sasaki, Hidefumi ^a   Shitara, Masayuki ^a   Yokota, Keisuke ^a   Hikosaka, Yu ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Copy number; Lung cancer; Mutation; Nuclear factor (erythroid derived 2) like 2; Squamous cell carcinoma

Indexed keywords

TRANSCRIPTION FACTOR NRF2;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE DOSAGE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE DOSAGE; GENOME, HUMAN; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; NEOPLASM STAGING; NF-E2-RELATED FACTOR 2; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SMOKING; STATISTICS, NONPARAMETRIC;

EID: 84863446184     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.921     Document Type: Article

References (28)

1. Ginsberg RJ, Kris MK and Armstrong JG: Cancer of the lung. In: Principles and Practice of Oncology. 4th edition. Lippincott, Philadelphia, PA, pp673-682, 1993.
2. Yasuda K, Ayabe H, Ide H and Uchida Y: Thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese Association for Thoracic Surgery. Committee of Science. Jpn J Thorac Cardiovasc Surg 48: 401-415, 1998.
3. Postmus PE: Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest 113 (Suppl 1): 28S-31S, 1998.
4. Kensler TW and Wakabayashi N: Nrf2, friend or foe for chemoprevention? Carcinogenesis 31: 90-99, 2010.
5. Moi P, Chank K, Asunis I, et al: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 91: 9926-9930, 1994. (Pubitemid 24311921)
6. Solis LM, Behrens C, Dong W, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16: 3743-3753, 2010.
7. Sasaki H, Hikosaka Y, Okuda K, et al: NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J Thorac Oncol 5: 786-789, 2010.
8. Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in Nrf2 impair its recognition by Keap1-Clu3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.
9. Hu Y, Ju Y, Lin D, et al: Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep 39: 4743-4747, 2012.
10. Merikallio H, Paakko P, Kinnula VL, et al: Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol 43: 577-584, 2012.
11. Yang H, Wang W, Zhang Y, et al: The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small cell lung carcinomas. Clin Lung Cancer 12: 166-171, 2011.
12. Mahaffey CM, Mahaffey NC, Holland W, et al: Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol 7: 34-39, 2012.
13. Endo K, Sasaki H, Yano M, et al: Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep 16: 533-541, 2006.
14. Wang TL, Maierhofer C, Speicher MR, et al: Digital karyotyping. Proc Natl Acad Sci USA 99: 16156-16161, 2002. (Pubitemid 35462765)
15. Zhao X, Weir BA, LaFramboise T, et al: Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570, 2005. (Pubitemid 40911156)
16. Okuda K, Sasaki H, Yukiue H, et al: Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 99: 2280-2285, 2008.
17. Takano T, Ohe Y, Sakamoto H, et al: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-6837, 2005.
18. Itoh K, Chiba T, Takahashi S, et al: An Nef2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997. (Pubitemid 27373291)
19. Rushmore TH and Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II detoxifying enzymes. Curr Drug Metab 3: 481-490, 2002. (Pubitemid 34987481)
20. Ngyyen T, Yang CS and Pickett CB: The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 37: 433-441, 2004. (Pubitemid 38901076)
21. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
22. Arisawa T, Tahara T, Shibata T, et al: Nrf2 gene promoter polymorphism and gastric carcinogenesis. Hepatogastroenterology 55: 750-754, 2008. (Pubitemid 351741541)
23. Semenza GL: HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
24. Zhou J, Scmid T, Schnitzer S, et al: Tumor hypoxia and cancer progression. Cancer Lett 237: 10-21, 2006.
25. Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15: 3423-3432, 2009.
26. Cho JM, Manandhar S, Lee HR, et al: Role of Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to tumor biology. Cancer Lett 260: 96-108, 2008.
27. Kim J-H, Bongner PN, Ramnath N, et al: Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res 13: 3875-3882, 2007. (Pubitemid 47037594)
28. Ohta T, Iijima K, Miyamoto M, et al: Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68: 1303-1309, 2008. (Pubitemid 351346836)